Bibliographie (2530)
RCT: Among children between the ages of 6 and 11 years with uncontrolled moderate-to-severe asthma, add-on Dupilumab reduced exacerbations and improved lung function.
jeudi, 09 décembre 2021 11:38 Écrit par Zouhair SouissiDupilumab in Children with Uncontrolled Moderate-to-Severe Asthma – New England Journal of Medicine Commentary: International study supports dupilumab for treatment of moderate-to-severe asthma in children – Vanderbilt University Medical Center
The post RCT: Among children between the ages of 6 and 11 years with uncontrolled moderate-to-severe asthma, add-on Dupilumab reduced exacerbations and improved lung function. appeared first on Links Medicus.
New Zealand to ban smoking for next generation in bid to outlaw habit by 2025 – “New legislation means the legal smoking age will increase every year, to create a smoke-free generation of New Zealanders”.
jeudi, 09 décembre 2021 11:38 Écrit par Zouhair SouissiNew Zealand to ban smoking for next generation in bid to outlaw habit by 2025 – The Guardian
The post New Zealand to ban smoking for next generation in bid to outlaw habit by 2025 – “New legislation means the legal smoking age will increase every year, to create a smoke-free generation of New Zealanders”. appeared first on Links Medicus.
![[Press release – not published yet] Lab study suggests a third dose (booster) of the Pfizer–BioNTech vaccine may be necessary to provide an adequate immune response to the Omicron variant.](/media/k2/items/cache/3badcacdb649d664d43a07493b4900e1_M.jpg)
[Press release – not published yet] Lab study suggests a third dose (booster) of the Pfizer–BioNTech vaccine may be necessary to provide an adequate immune response to the Omicron variant.
jeudi, 09 décembre 2021 11:38 Écrit par Zouhair SouissiPress release: Pfizer and Biontech provide update on Omicron variant Commentaries: Omicron likely to weaken COVID vaccine protection – Nature Pfizer-BioNTech says COVID booster should protect against Omicron – CIDRAP Expert reaction to press release from Pfizer-BioNTech about omicron and neutralising antibody titres after two and three vaccine doses – Science Media Centre Covid: Pfizer […]
The post [Press release – not published yet] Lab study suggests a third dose (booster) of the Pfizer–BioNTech vaccine may be necessary to provide an adequate immune response to the Omicron variant. appeared first on Links Medicus.
As 57 countries report Omicron cases, Pfizer says its boosters offer protection – but WHO cautions more research is needed.
jeudi, 09 décembre 2021 11:38 Écrit par Zouhair SouissiAs 57 Countries Report Omicron Cases, Pfizer Says its Boosters Offer Protection – But WHO Cautions More Research is Needed – Health Policy Watch See also: Covid: Vaccines should work against Omicron variant, WHO says – BBC
The post As 57 countries report Omicron cases, Pfizer says its boosters offer protection – but WHO cautions more research is needed. appeared first on Links Medicus.
Large observational study in Israel showed a third dose (booster) of the Pfizer–BioNTech vaccine had 90% effectiveness at preventing death due to Covid-19 compared to a two-dose regimen.
jeudi, 09 décembre 2021 11:38 Écrit par Zouhair SouissiBNT162b2 Vaccine Booster and Mortality Due to Covid-19 – New England Journal of Medicine Editorial: Booster Doses and Prioritizing Lives Saved
The post Large observational study in Israel showed a third dose (booster) of the Pfizer–BioNTech vaccine had 90% effectiveness at preventing death due to Covid-19 compared to a two-dose regimen. appeared first on Links Medicus.
Large observational study in Israel showed a third dose (booster) of the Pfizer–BioNTech reduced the rates of confirmed Covid-19 and severe illness compared to a two-dose regimen.
jeudi, 09 décembre 2021 11:38 Écrit par Zouhair SouissiProtection against Covid-19 by BNT162b2 Booster across Age Groups – New England Journal of Medicine Editorial: Booster Doses and Prioritizing Lives Saved
The post Large observational study in Israel showed a third dose (booster) of the Pfizer–BioNTech reduced the rates of confirmed Covid-19 and severe illness compared to a two-dose regimen. appeared first on Links Medicus.
Beyond Omicron: what’s next for COVID’s viral evolution.
mercredi, 08 décembre 2021 11:54 Écrit par Zouhair SouissiBeyond Omicron: what’s next for COVID’s viral evolution – Nature
The post Beyond Omicron: what’s next for COVID’s viral evolution. appeared first on Links Medicus.
ESC Position Paper: Optimal follow-up after acute pulmonary embolism.
mercredi, 08 décembre 2021 11:54 Écrit par Zouhair SouissiOptimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society – European Heart Journal Commentary on Twitter Do you […]
The post ESC Position Paper: Optimal follow-up after acute pulmonary embolism. appeared first on Links Medicus.
RCT: In patients with severe Covid-19, high-flow oxygen therapy reduced the likelihood of invasive mechanical ventilation and decreased the time to clinical recovery compared to conventional oxygen therapy.
mercredi, 08 décembre 2021 11:54 Écrit par Zouhair SouissiEffect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19: A Randomized Clinical Trial – JAMA Related: Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research – “The two randomized controlled trials indicate superiority of […]
The post RCT: In patients with severe Covid-19, high-flow oxygen therapy reduced the likelihood of invasive mechanical ventilation and decreased the time to clinical recovery compared to conventional oxygen therapy. appeared first on Links Medicus.
Phase 2 RCT: Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule.
mercredi, 08 décembre 2021 11:54 Écrit par Zouhair SouissiImmunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials – The Lancet Infectious Diseases Invited Commentary: Booster doses for inactivated COVID-19 vaccines: if, when, and for whom – The Lancet Infectious Diseases
The post Phase 2 RCT: Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule. appeared first on Links Medicus.
